Oak Hill Bio Announces Dosing of First Participant in BEACON Phase 3 Clinical Trial of Rugonersen in Angelman Syndrome
Rugonersen, a potentially best-in-class antisense oligonucleotide (ASO) therapy in development for Angelman syndrome, advanced into the pivotal Phase 3 BEACON clinical trial Angelman syndrome affects approximately 30,000 diagnosed individuals in the US and EU5 and has no approved treatments Topline data expected in early 2029 Cambridge (United States), July 28, 2026 – OHB Pediatrics […]